CD19 and leukemia: Furthermore, in a CD19+ Nalm6 xenograft leukemia model, treatment with the enhanced CAR‐T cells resulted in 100% survival at 33 days, while treatment with normal CAR‐T cells resulted in a median survival of only 24 days (Figure 1).